Form 4: Pacira BioSciences Director Equity Grant Disclosure

Director Mark Froimson received a grant of restricted stock units and stock options as part of annual compensation.

Summary

• Director Mark Froimson was granted 6,405 restricted stock units (RSUs) on June 10, 2026.
• Director Mark Froimson was granted 10,891 stock options with an exercise price of $23.42 on June 10, 2026.
• Both the RSUs and the stock options are subject to a one-year vesting period, becoming exercisable on June 10, 2027.
• Following these transactions, the director's total direct beneficial ownership of common stock is 26,541 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standard retention mechanism via one-year cliff vesting requirements.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though minor in scale.

Risks

• Vesting is contingent upon the director remaining in continuous service with the issuer.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director compensation.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance practice for mid-cap biotechnology firms, where equity grants are used to attract and retain board members.

Comparison to Industry Standards

• The use of RSU and option grants for board compensation is consistent with standard practices for NASDAQ-listed life sciences companies.
• A one-year vesting schedule for annual director grants is typical for companies of this size.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity grants on June 10, 2027.

Key Dates

Keywords

Pacira BioSciences, PCRX, Form 4, Insider Trading, Equity Compensation, Director Compensation